Across TCGA pan-cancer cohorts, LYL1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LYL1 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher LYL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LYL1 expression acts as an unfavorable survival marker.
COAD and PRAD are the cancer types where LYL1 Mutation most reproducibly stratifies survival.